CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 128 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,495,089 | +110.6% | 50,272 | +27.6% | 0.01% | +150.0% |
| Q2 2023 | $709,952 | +27.1% | 39,398 | +13.3% | 0.00% | 0.0% |
| Q1 2023 | $558,358 | -14.8% | 34,767 | -2.9% | 0.00% | 0.0% |
| Q4 2022 | $655,030 | -12.4% | 35,794 | -6.0% | 0.00% | 0.0% |
| Q3 2022 | $748,000 | +9.7% | 38,097 | +4.2% | 0.00% | 0.0% |
| Q2 2022 | $682,000 | -49.3% | 36,570 | -40.3% | 0.00% | -33.3% |
| Q1 2022 | $1,346,000 | -30.5% | 61,300 | -10.1% | 0.00% | -25.0% |
| Q4 2021 | $1,938,000 | +138.4% | 68,200 | +76.7% | 0.00% | +100.0% |
| Q3 2021 | $813,000 | +11.7% | 38,600 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $728,000 | +23.4% | 38,600 | 0.0% | 0.00% | +100.0% |
| Q1 2021 | $590,000 | +8.3% | 38,600 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $545,000 | -19.9% | 38,600 | -11.1% | 0.00% | -50.0% |
| Q3 2020 | $680,000 | +126.7% | 43,400 | +153.8% | 0.00% | +100.0% |
| Q2 2020 | $300,000 | +19.5% | 17,100 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $251,000 | -39.7% | 17,100 | +3.0% | 0.00% | 0.0% |
| Q4 2019 | $416,000 | +66.4% | 16,600 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $250,000 | +3.3% | 16,600 | +71.1% | 0.00% | 0.0% |
| Q2 2019 | $242,000 | +12.0% | 9,700 | +2.1% | 0.00% | 0.0% |
| Q1 2019 | $216,000 | -2.7% | 9,500 | +28.4% | 0.00% | 0.0% |
| Q4 2018 | $222,000 | – | 7,400 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |